m9140
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 4, 2022 (NCT05464030)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06710132 | Phase 1/Phase 2 (Phase 2) | Feb 15, 2025 | Merck KGaA, Merck Serono |
| NCT06806046 | Phase 1 | Dec 20, 2024 | Merck KGaA |
| NCT05464030 | Phase 1 | Aug 4, 2022 | Merck KGaA, Merck Serono |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 3 | 1 | 2 | 2022 |
| Merck Serono | For profit | 2 | 2 | 2 | 2022 |
2 organizations
Page 1 / 1